@doepke_michel Michel Doepke
Michel Doepke posts on X about $lly, $nvo, $mrk, $nktr the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.
Engagements: [-----] #
- [--] Week [-------] -19%
- [--] Month [-------] -3.10%
- [--] Months [---------] +88%
- [--] Year [---------] +111%
Mentions: [--] #
- [--] Week [---] +17%
- [--] Month [---] +2.20%
- [--] Months [-----] +54%
- [--] Year [-----] +103%
Followers: [-----] #
- [--] Week [-----] +0.42%
- [--] Month [-----] +3.50%
- [--] Months [-----] +24%
- [--] Year [-----] +53%
CreatorRank: [-------] #
Social Influence
Social category influence stocks 69.48% finance 14.86% cryptocurrencies 6.43% countries 2.81% currencies 2.01% technology brands 1.2% financial services 1.2% travel destinations 0.4%
Social topic influence $lly #6, $nvo #146, $mrk #24, $nktr #38, $sny #21, $tern #5, $pfe #66, strong 4.82%, in the 4.42%, $vtyx #9
Top accounts mentioned or mentioned by @biopharmiq @dudebiotech @zohmbastic @seedy19tron @giger1964 @joserestonva @persimmonti @biohazard3737 @libe @aafree @trader53 @jacobplieth @doepkemichel @meangenebio @bigchodu @pdufa_pulse @kittikatten @franca_ole @bio_clouseau @savoryseaw50174
Top assets mentioned Eli Lilly and Company (LLY) Novo-Nordisk (NVO) Merck & Co., Inc. (MRK) Synthetify (SNY) Terns Pharmaceuticals, Inc. (TERN) Pfizer, Inc. (PFE) Ventyx Biosciences, Inc. (VTYX) Viking Therapeutics, Inc (VKTX) BioAge Labs, Inc. (BIOA) Bristol-Myers Squibb Co (BMY) Novartis AG (NVS) Abivax SA (ABVX) Neumora Therapeutics, Inc. (NMRA) Amgen, Inc. (AMGN) AbbVie Inc (ABBV) Kyverna Therapeutics, Inc. (KYTX) Neurocrine Biosciences, Inc. (NBIX) Crinetics Pharmaceuticals, Inc. (CRNX) Metsera, Inc. (MTSR) Day One Biopharmaceuticals, Inc. (DAWN) Kymera Therapeutics, Inc. (KYMR) Biogen Inc (BIIB) Vertex Protocol (VRTX) uniQure N.V. (QURE) BridgeBio Pharma, Inc. Common Stock (BBIO) Alnylam Pharmaceuticals, Inc. (ALNY) Ocular Therapeutix, Inc. (OCUL) Cytokinetics Inc. (CYTK) Immunocore Holdings Limited (IMCR) AstraZeneca PLC (AZN) Incyte Corporation (INCY) Exelixis Inc (EXEL) Revolution Medicines, Inc. (RVMD) Sanofi (SNY) Hims & Hers Health, Inc. (HIMS) Cogent Biosciences, Inc. Common Stock (COGT) Pharvaris, B.V. (PHVS) Praxis Precision Medicines, Inc. (PRAX) GRAIL, Inc. Common Stock (GRAL) Karuna Therapeutics, Inc. Common Stock (KRTX) One Cash (ONC) MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Arrowhead Research Corporation (ARWR) Summit Therapeutics Inc. Common Stock (SMMT) Gilead Sciences, Inc. (GILD) GSK plc (GSK) Celldex Therapeutics, Inc (CLDX) Blueprint Medicines Corporation (BPMC) Seagen Inc (SGEN) Array Technologies, Inc. (ARRY) Johnson & Johnson (JNJ)
Top Social Posts
Top posts by engagements in the last [--] hours
"$NBIX MS ("EW" PT from $175 to $173): "Crenessity outperforms. Launch metrics show strong path to potential blockbuster with $135M 4Q sales and 80% reimbursement." Increasing FY26 Crenessity revenues to $600M (from $396M). $CRNX $NBIX #Crenessity growth is impressive. Bodes well for a potential launch of Atumelnant from $CRNX for the treatment of CAH in the long-term. https://t.co/X6bpPvKQAr $NBIX #Crenessity growth is impressive. Bodes well for a potential launch of Atumelnant from $CRNX for the treatment of CAH in the long-term. https://t.co/X6bpPvKQAr"
X Link 2026-02-12T09:57Z [----] followers, [----] engagements
"$ENTA to Present Preclinical Data for EDP-978 its KIT Inhibitor in Development for the Treatment of Type [--] Immune Diseases at the [----] AAAAI Annual Meeting. $CLDX $BPMC $SNY $COGT $JSPR https://www.businesswire.com/news/home/20260210569136/en/Enanta-Pharmaceuticals-to-Present-Preclinical-Data-for-EDP-978-its-KIT-Inhibitor-in-Development-for-the-Treatment-of-Type-2-Immune-Diseases-at-the-2026-AAAAI-Annual-Meeting"
X Link 2026-02-10T12:03Z [----] followers, [---] engagements
"$LLY Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer https://www.prnewswire.com/news-releases/lillys-retevmo-selpercatinib-delivers-substantial-event-free-survival-benefit-as-an-adjuvant-therapy-in-early-stage-ret-fusion-positive-lung-cancer-302687923.html https://www.prnewswire.com/news-releases/lillys-retevmo-selpercatinib-delivers-substantial-event-free-survival-benefit-as-an-adjuvant-therapy-in-early-stage-ret-fusion-positive-lung-cancer-302687923.html"
X Link 2026-02-16T12:25Z [----] followers, [----] engagements
"$LLY $LOXO #Retevmo - more readouts to come. $RIGL https://investor.lilly.com/static-files/45a92498-43d0-4e2d-a4e6-a9131841cfd6 $LLY Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer https://t.co/21Ea2NCe3Q https://investor.lilly.com/static-files/45a92498-43d0-4e2d-a4e6-a9131841cfd6 $LLY Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer https://t.co/21Ea2NCe3Q"
X Link 2026-02-16T13:23Z [----] followers, [----] engagements
"$BBIO is only $5B worth. #Attruby alone could generate peak sales of $3B - depending on the sales development of the competitors $ALNY and $PFE. Just the #Acoramidis asset justifies the current valuation. Great pipeline on top"
X Link 2024-12-06T13:46Z [----] followers, 19.3K engagements
"$BONEX #Bonesupport 🦴🦴🦴🚀🚀🚀 $BONEX #Bonesupport slight miss top-line but impressive EBIT beat. More high profitable growth to come. Shares should outperform today imo. https://t.co/p8SJ4wlGBt https://t.co/quEziioVAo $BONEX #Bonesupport slight miss top-line but impressive EBIT beat. More high profitable growth to come. Shares should outperform today imo. https://t.co/p8SJ4wlGBt https://t.co/quEziioVAo"
X Link 2025-02-25T08:02Z [----] followers, [----] engagements
"$GUBRA $ABBV 🥳🥳🥳 Wow: Under the terms of the agreement $ABBV will lead development and commercialization activities of GUB014295 globally. $GUBRA will receive $350 million in total upfront payment and will be eligible to receive up to $1.875 billion in development commercial and sales milestone Wow: Under the terms of the agreement $ABBV will lead development and commercialization activities of GUB014295 globally. $GUBRA will receive $350 million in total upfront payment and will be eligible to receive up to $1.875 billion in development commercial and sales milestone"
X Link 2025-03-03T08:04Z [----] followers, [----] engagements
"$OSSD next stop ATH - more and more people realize that there is another high margin medtech growth story in the making. $BONEX #Bonesupport [---] 🦴🦴 $OSSD Q2 sales up 73% 🔥🔥🔥https://t.co/v78G5nfJXQ https://t.co/VDm43sxvWh $OSSD Q2 sales up 73% 🔥🔥🔥https://t.co/v78G5nfJXQ https://t.co/VDm43sxvWh"
X Link 2025-08-19T12:16Z [----] followers, [----] engagements
"$OCUL takeover speculation betaville. https://seekingalpha.com/news/4492779-ocular-therapeutix-gains-amid-takeover-speculation https://seekingalpha.com/news/4492779-ocular-therapeutix-gains-amid-takeover-speculation"
X Link 2025-09-05T18:48Z [----] followers, [----] engagements
"#Verisure is a partner of $PLEJD #Plejd. It could be Europes biggest listing in three years. https://www.verisure.com/press-releases/regulatory/verisure-announces-its-intention-to-list-its-shares-on-nasdaq-stockholm Alarm firm Verisure backed by Hellman & Friedman plans a [---] billion IPO in Stockholm set to be Europes biggest listing in three years https://t.co/2RSmJ7eTFU https://www.verisure.com/press-releases/regulatory/verisure-announces-its-intention-to-list-its-shares-on-nasdaq-stockholm Alarm firm Verisure backed by Hellman & Friedman plans a [---] billion IPO in Stockholm set to be"
X Link 2025-09-17T06:08Z [----] followers, [----] engagements
"$MRK $VRNA Transaction expected to be closed today. https://www.veronapharma.com/news/shareholders-of-verona-pharma-approve-proposed-acquisition-by-merck/ https://www.veronapharma.com/news/shareholders-of-verona-pharma-approve-proposed-acquisition-by-merck/"
X Link 2025-10-07T08:48Z [----] followers, [----] engagements
"nHCM landscape (source: Barclays). $CYTK $LXRX $EWTX $TNYA $LXEO"
X Link 2025-10-10T11:25Z [----] followers, [----] engagements
"@PersimmonTI @Biohazard3737 Winning overpriced M&A transactions. $GBT $TRIL $ARNA $SGEN $ARRY"
X Link 2025-11-08T16:44Z [----] followers, [---] engagements
"$CAMX reports positive topline results for CAM2056 semaglutide monthly depot. $NVO $LLY https://www.camurus.com/media/press-releases/2025/camurus-reports-positive-topline-results-for-cam2056-semaglutide-monthly-depot/ https://www.camurus.com/media/press-releases/2025/camurus-reports-positive-topline-results-for-cam2056-semaglutide-monthly-depot/"
X Link 2025-11-10T07:30Z [----] followers, 12.8K engagements
"$LEGN Q3 results. Carvykti net trade sales of approximately $524M. $JNJ https://www.globenewswire.com/news-release/2025/11/12/3186056/0/en/Legend-Biotech-Reports-Third-Quarter-2025-Results-and-Recent-Highlights.html https://www.globenewswire.com/news-release/2025/11/12/3186056/0/en/Legend-Biotech-Reports-Third-Quarter-2025-Results-and-Recent-Highlights.html"
X Link 2025-11-12T12:04Z [----] followers, [----] engagements
"$MRK $VRNA 🤔🤔🤔Withdrawal of application in the EU. https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-november-2025 https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-november-2025"
X Link 2025-11-14T12:51Z [----] followers, [---] engagements
"T-knife Therapeutics Files Clinical Trial Application for Phase [--] ATLAS Trial for TK-6302 a Supercharged PRAME-targeted T Cell Receptor Therapy. $IMTX $IMCR https://www.globenewswire.com/news-release/2025/11/17/3189058/0/en/T-knife-Therapeutics-Files-Clinical-Trial-Application-for-Phase-1-ATLAS-Trial-for-TK-6302-a-Supercharged-PRAME-targeted-T-Cell-Receptor-Therapy.html https://www.globenewswire.com/news-release/2025/11/17/3189058/0/en/T-knife-Therapeutics-Files-Clinical-Trial-Application-for-Phase-1-ATLAS-Trial-for-TK-6302-a-Supercharged-PRAME-targeted-T-Cell-Receptor-Therapy.html"
X Link 2025-11-17T13:02Z [----] followers, [----] engagements
"$SGEN ($43B) $ARNA ($7B) $GBT ($5B) $ARRY ($11B) $MTSR ($8B upfront) $TRIL ($2B) $MDVN ($14B) $BHVN ($12B) = $102B. $PFE market cap: $144B"
X Link 2025-11-18T15:25Z [----] followers, 131.5K engagements
"$BRKR life science recovery + AI metrology fantasy. 👇 Added $BRKR Added $BRKR"
X Link 2025-11-20T15:00Z [----] followers, [----] engagements
"$BRKR beauty. Good entry 👇 Added $BRKR Added $BRKR"
X Link 2025-11-26T10:18Z [----] followers, [----] engagements
"$AZN #Astrazeneca Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension. PDUFA date is anticipated during the second quarter of [----] following use of a Priority Review voucher. $MLYS https://news.cision.com/se/astrazeneca/r/baxdrostat-new-drug-application-accepted-under-fda-priority-review-in-the-us-for-patients-with-hard-c4275582utm_source=dlvr.it&utm_medium=twitter"
X Link 2025-12-02T08:09Z [----] followers, [----] engagements
"$PHVS $RPRX $PHVS Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks https://t.co/E8DeyRvQdP $PHVS Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks https://t.co/E8DeyRvQdP"
X Link 2025-12-03T11:57Z [----] followers, [----] engagements
"$DNLI and $RPRX Announce $275 Million Royalty Funding Agreement https://www.globenewswire.com/news-release/2025/12/04/3199643/0/en/Denali-Therapeutics-and-Royalty-Pharma-Announce-275-Million-Royalty-Funding-Agreement.html https://www.globenewswire.com/news-release/2025/12/04/3199643/0/en/Denali-Therapeutics-and-Royalty-Pharma-Announce-275-Million-Royalty-Funding-Agreement.html"
X Link 2025-12-04T12:02Z [----] followers, [----] engagements
"$PRAX Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor https://www.globenewswire.com/news-release/2025/12/04/3200309/0/en/Praxis-Precision-Medicines-Announces-Positive-Pre-NDA-Meeting-with-FDA-for-Ulixacaltamide-in-Essential-Tremor.html https://www.globenewswire.com/news-release/2025/12/04/3200309/0/en/Praxis-Precision-Medicines-Announces-Positive-Pre-NDA-Meeting-with-FDA-for-Ulixacaltamide-in-Essential-Tremor.html"
X Link 2025-12-04T21:04Z [----] followers, [----] engagements
"$IMTX Announces $125 Million Underwritten Offering at $10 per share. I really like the company and the pipeline but they did too many offerings in the past imo. Consequently the stock has not really moved in the last [--] years (was a SPAC deal) $IMCR https://investors.immatics.com/news-releases/news-release-details/immatics-announces-125-million-underwritten-offering https://investors.immatics.com/news-releases/news-release-details/immatics-announces-125-million-underwritten-offering"
X Link 2025-12-05T12:19Z [----] followers, [----] engagements
"$PCSC Freenome and Perceptive Capital Solutions Corp Announce Business Combination Agreement to Create a Publicly Listed Company Transforming Blood-Based Multi-Cancer Detection through an AI/ML-Enabled Multiomics Platform. $GRAL $ILMN $EXAS https://www.freenome.com/newsroom/freenome-and-perceptive-capital-solutions-corp-announce-business-combination-agreement-to-create-a-publicly-listed-company-transforming-blood-based-multi-cancer-detection-through-an-ai-ml-enabled-mult/"
X Link 2025-12-05T13:53Z [----] followers, [----] engagements
"$NRIX Presents New Data Demonstrating Durable Deepening Responses in Phase [--] Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia at #ASH25. https://www.globenewswire.com/news-release/2025/12/06/3201064/0/en/Nurix-Therapeutics-Presents-New-Data-Demonstrating-Durable-Deepening-Responses-in-Phase-1-Trial-of-Bexobrutideg-NX-5948-in-Patients-with-Relapsed-or-Refractory-Chronic-Lymphocytic-.html"
X Link 2025-12-06T17:59Z [----] followers, [----] engagements
"$COGT Presents Full SUMMIT Results ofBezuclastinibinPatientswithNonAdvancedSystemic Mastocytosis (NonAdvSM)at the67thAnnual Meeting of the American Society of Hematology (ASH) $BPMC $SNY https://www.globenewswire.com/news-release/2025/12/06/3201063/0/en/Cogent-Biosciences-Presents-Full-SUMMIT-Results-of-Bezuclastinib-in-Patients-with-NonAdvanced-Systemic-Mastocytosis-NonAdvSM-at-the-67th-Annual-Meeting-of-the-American-Society-of-H.html"
X Link 2025-12-06T18:00Z [----] followers, [----] engagements
"$ZLAB Announces Updates to Chinas National Reimbursement Drug List https://www.businesswire.com/news/home/20251206866125/en/Zai-Lab-Announces-Updates-to-Chinas-National-Reimbursement-Drug-List https://www.businesswire.com/news/home/20251206866125/en/Zai-Lab-Announces-Updates-to-Chinas-National-Reimbursement-Drug-List"
X Link 2025-12-07T09:57Z [----] followers, [----] engagements
"$ZEAL and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases https://www.globenewswire.com/news-release/2025/12/11/3203616/0/en/Zealand-Pharma-and-OTR-Therapeutics-enter-multi-program-strategic-collaboration-and-license-agreement-to-develop-novel-therapeutics-for-metabolic-diseases.html_gl=1*i3xvo*_up*MQ.*_ga*MjExMzcyNzYzMi4xNzY1NDM2ODg0*_ga_ERWPGTJ5X8*czE3NjU0MzY4ODQkbzEkZzAkdDE3NjU0MzY5NDckajYwJGwwJGgw"
X Link 2025-12-11T07:09Z [----] followers, [----] engagements
"$PHG #Philips agrees to acquire SpectraWAVE Inc. advancing next-generation coronary intravascular imaging and physiological assessment with AI https://www.globenewswire.com/news-release/2025/12/15/3205131/0/en/Philips-agrees-to-acquire-SpectraWAVE-Inc-advancing-next-generation-coronary-intravascular-imaging-and-physiological-assessment-with-AI.html_gl=1*1l6z6ml*_up*MQ.*_ga*MTYyMzgxNzUxMy4xNzY1NzgyMDU1*_ga_ERWPGTJ5X8*czE3NjU3ODIwNTUkbzEkZzAkdDE3NjU3ODIwNTckajU4JGwwJGgw"
X Link 2025-12-15T07:01Z [----] followers, [----] engagements
"$ADPT Announces Two Immune Receptor Licensing Agreements with $PFE. Upfront payment + milestones that could total up to about $890 million. https://www.globenewswire.com/news-release/2025/12/15/3205383/0/en/Adaptive-Biotechnologies-Announces-Two-Immune-Receptor-Licensing-Agreements-with-Pfizer.html https://www.globenewswire.com/news-release/2025/12/15/3205383/0/en/Adaptive-Biotechnologies-Announces-Two-Immune-Receptor-Licensing-Agreements-with-Pfizer.html"
X Link 2025-12-15T14:10Z [----] followers, [----] engagements
"$BCYC Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline https://www.businesswire.com/news/home/20251215037659/en/Bicycle-Therapeutics-Establishes-Multiple-Strategic-Partnerships-to-Create-End-to-End-Supply-Chain-to-Support-its-Wholly-Owned-Radiopharmaceutical-Pipeline https://www.businesswire.com/news/home/20251215037659/en/Bicycle-Therapeutics-Establishes-Multiple-Strategic-Partnerships-to-Create-End-to-End-Supply-Chain-to-Support-its-Wholly-Owned-Radiopharmaceutical-Pipeline"
X Link 2025-12-16T06:07Z [----] followers, [----] engagements
"$NKTR Rezpeg vs. Olumiant $INCY $LLY"
X Link 2025-12-16T13:09Z [----] followers, 10.6K engagements
"Five European Biotech Stocks Face Pivotal Trial Results in [----]. $ABVX $VLA $ARGX $ZEAL $INV #Abivax: The stock setup into [----] is favorable with two major catalysts on deck Wolfe Research analyst Andy Chen wrote in a note. https://www.bloomberg.com/news/articles/2025-12-18/five-european-biotech-stocks-face-pivotal-trial-results-in-2026 https://www.bloomberg.com/news/articles/2025-12-18/five-european-biotech-stocks-face-pivotal-trial-results-in-2026"
X Link 2025-12-18T13:19Z [----] followers, [----] engagements
"$KALV Announces Approval of EKTERLY (sebetralstat) in Japan First and Only Oral On-demand Treatment for Hereditary Angioedema. $PHVS https://www.businesswire.com/news/home/20251222393408/en/KalVista-Pharmaceuticals-Announces-Approval-of-EKTERLY-sebetralstat-in-Japan-First-and-Only-Oral-On-demand-Treatment-for-Hereditary-Angioedema https://www.businesswire.com/news/home/20251222393408/en/KalVista-Pharmaceuticals-Announces-Approval-of-EKTERLY-sebetralstat-in-Japan-First-and-Only-Oral-On-demand-Treatment-for-Hereditary-Angioedema"
X Link 2025-12-22T11:26Z [----] followers, [----] engagements
"$VRDN Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease. PDUFA date June [--] [----]. https://www.businesswire.com/news/home/20251222159703/en/Viridian-Therapeutics-Announces-BLA-Acceptance-and-Priority-Review-for-Veligrotug-for-the-Treatment-of-Thyroid-Eye-Disease https://www.businesswire.com/news/home/20251222159703/en/Viridian-Therapeutics-Announces-BLA-Acceptance-and-Priority-Review-for-Veligrotug-for-the-Treatment-of-Thyroid-Eye-Disease"
X Link 2025-12-22T12:01Z [----] followers, [----] engagements
"Two years ago at Christmas $BMY made shareholders of two biotech companies happy: $KRTX and $RYZB. Will $LLY now provide a Christmas gift $ABVX https://www.bms.com/media/press-releases.html https://www.bms.com/media/press-releases.html"
X Link 2025-12-22T14:51Z [----] followers, [----] engagements
"$PRAX Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor https://www.globenewswire.com/news-release/2025/12/29/3210888/0/en/Praxis-Precision-Medicines-Announces-the-FDA-Has-Granted-Breakthrough-Therapy-Designation-for-Ulixacaltamide-HCl-in-Essential-Tremor.html https://www.globenewswire.com/news-release/2025/12/29/3210888/0/en/Praxis-Precision-Medicines-Announces-the-FDA-Has-Granted-Breakthrough-Therapy-Designation-for-Ulixacaltamide-HCl-in-Essential-Tremor.html"
X Link 2025-12-29T13:07Z [----] followers, [----] engagements
"$GMAB #Genmab to discontinue clinical development of acasunlimab following a portfolio review. $BNTX https://www.globenewswire.com/news-release/2025/12/29/3210905/0/en/Genmab-Portfolio-Prioritization-Update.html_gl=1*1up3jlt*_up*MQ.*_ga*MTY3MjQ0NTc3Mi4xNzY3MDE1MjQ3*_ga_ERWPGTJ5X8*czE3NjcwMTUyNDckbzEkZzAkdDE3NjcwMTUyNjAkajQ3JGwwJGgw https://www.globenewswire.com/news-release/2025/12/29/3210905/0/en/Genmab-Portfolio-Prioritization-Update.html_gl=1*1up3jlt*_up*MQ.*_ga*MTY3MjQ0NTc3Mi4xNzY3MDE1MjQ3*_ga_ERWPGTJ5X8*czE3NjcwMTUyNDckbzEkZzAkdDE3NjcwMTUyNjAkajQ3JGwwJGgw"
X Link 2025-12-29T13:34Z [----] followers, [----] engagements
"$GUBRA Announces Expansion of Facilities to Support Continued Growth Across Its Businesses. https://www.gubra.dk/mfn_news/gubra-announces-expansion-of-facilities-to-support-continued-growth-across-its-businesses/ https://www.gubra.dk/mfn_news/gubra-announces-expansion-of-facilities-to-support-continued-growth-across-its-businesses/"
X Link 2026-01-02T06:33Z [----] followers, [----] engagements
"JPM Healthcare Conference ahead. Which company might be acquired Own shares of $PTGX $ABVX and $TERN $PTGX $ABVX Other please comment $TERN $PTGX $ABVX Other please comment $TERN"
X Link 2026-01-02T22:12Z [----] followers, [----] engagements
"$IDIA #Idorsia JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension https://www.globenewswire.com/news-release/2026/01/05/3212417/0/en/Idorsia-s-JERAYGO-aprocitentan-approved-in-Canada-for-the-treatment-of-resistant-hypertension.html_gl=1*1772wu5*_up*MQ.*_ga*MTk1NzgxMzI4OS4xNzY3NTkyODcz*_ga_ERWPGTJ5X8*czE3Njc1OTI4NzIkbzEkZzAkdDE3Njc1OTI4NzUkajU3JGwwJGgw"
X Link 2026-01-05T06:02Z [----] followers, [----] engagements
"$NMRA Highlights [----] Pipeline Strategy and Anticipated Upcoming Milestones. #Obesity 🤓 https://www.globenewswire.com/news-release/2026/01/05/3212570/0/en/Neumora-Therapeutics-Highlights-2026-Pipeline-Strategy-and-Anticipated-Upcoming-Milestones.html_gl=1*wc1dog*_up*MQ.*_ga*ODE3NjU0MTY2LjE3Njc2MTMyNjM.*_ga_ERWPGTJ5X8*czE3Njc2MTMyNjMkbzEkZzAkdDE3Njc2MTMyNjMkajYwJGwwJGgw"
X Link 2026-01-05T11:42Z [----] followers, [----] engagements
"$GUTS Enters a Catalyst-Rich [----] Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category https://www.globenewswire.com/news-release/2026/01/05/3212610/0/en/Fractyl-Health-Enters-a-Catalyst-Rich-2026-Positioned-to-Define-the-Post-GLP-1-Weight-Maintenance-Therapeutic-Category.html_gl=1*1wf81kt*_up*MQ.*_ga*MTQ5OTU5MTQ4OS4xNzY3NjE0NDI5*_ga_ERWPGTJ5X8*czE3Njc2MTQ0MjgkbzEkZzAkdDE3Njc2MTQ1ODYkajM5JGwwJGgw"
X Link 2026-01-05T12:03Z [----] followers, 15.6K engagements
"$INCY Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi/Minjuvi) as a First-line Treatment for Diffuse Large B-Cell Lymphoma https://www.businesswire.com/news/home/20260105730167/en/Incyte-Announces-Positive-Topline-Results-from-Pivotal-Study-of-Tafasitamab-MonjuviMinjuvi-as-a-First-line-Treatment-for-Diffuse-Large-B-Cell-Lymphoma https://www.businesswire.com/news/home/20260105730167/en/Incyte-Announces-Positive-Topline-Results-from-Pivotal-Study-of-Tafasitamab-MonjuviMinjuvi-as-a-First-line-Treatment-for-Diffuse-Large-B-Cell-Lymphoma"
X Link 2026-01-05T12:32Z [----] followers, [----] engagements
"$SLNO Announces Publication of Results from Pivotal Study of VYKAT XR in the Journal of Clinical Endocrinology and Metabolism https://www.globenewswire.com/news-release/2026/01/05/3212687/0/en/Soleno-Therapeutics-Announces-Publication-of-Results-from-Pivotal-Study-of-VYKAT-XR-in-the-Journal-of-Clinical-Endocrinology-and-Metabolism.html_gl=1*c277z1*_up*MQ.*_ga*NTQ5MTA0MzExLjE3Njc2MTgwNjI.*_ga_ERWPGTJ5X8*czE3Njc2MTgwNjEkbzEkZzAkdDE3Njc2MTgxMzEkajYwJGwwJGgw"
X Link 2026-01-05T13:02Z [----] followers, [----] engagements
"$CRNX I know early days. But Atumelnant could become a treatment option for CAH if successful. $NBIX recently reported a strong launch with its potential competitor CRENESSITY. Today's news has reinforced my M&A case. Long Crinetics"
X Link 2026-01-05T13:40Z [----] followers, [----] engagements
"$CRNX slides online. $NBIX https://s206.q4cdn.com/492797646/files/doc_events/2026/01/FINAL_January-2026-CRNX-Corporate-Update.pdf https://s206.q4cdn.com/492797646/files/doc_events/2026/01/FINAL_January-2026-CRNX-Corporate-Update.pdf"
X Link 2026-01-05T14:04Z [----] followers, [----] engagements
"$LLY in talks to buy $VTYX for more than $1 billion WSJ reports https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-talks-buy-ventyx-biosciences-more-than-1-billion-deal-wsj-reports-2026-01-06/ https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-talks-buy-ventyx-biosciences-more-than-1-billion-deal-wsj-reports-2026-01-06/"
X Link 2026-01-07T06:09Z [----] followers, [----] engagements
"$AMGN acquires Dark Blue Therapeutics bolstering oncology pipeline. $KURA $SNDX https://www.amgen.com/newsroom/press-releases/2026/01/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline https://www.amgen.com/newsroom/press-releases/2026/01/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline"
X Link 2026-01-07T06:38Z [----] followers, [----] engagements
"UBS pharma/biotech research update. Top Picks: $APGE $COGT $KOD $IDYA $IVA $SABS and - $VTYX. 🤓Pharma Top Picks are $LLY and $MRK"
X Link 2026-01-07T09:06Z [----] followers, [----] engagements
"$EXEL and $NTRA to Collaborate on STELLAR-316 a Phase [--] Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer https://www.businesswire.com/news/home/20260107329077/en/Exelixis-and-Natera-to-Collaborate-on-STELLAR-316-a-Phase-3-Pivotal-Trial-of-Zanzalintinib-for-Patients-with-Colorectal-Cancer https://www.businesswire.com/news/home/20260107329077/en/Exelixis-and-Natera-to-Collaborate-on-STELLAR-316-a-Phase-3-Pivotal-Trial-of-Zanzalintinib-for-Patients-with-Colorectal-Cancer"
X Link 2026-01-07T13:01Z [----] followers, [----] engagements
"$RVMD - $ABBV interested. Some oncology names are on fire now $VSTM $TERN $KURA $SNDX $IDYA $ABBV Near Deal for $RVMD. $VSTM sympathy play. https://t.co/3kV0WivXQs https://t.co/X8Gqg92jSG $ABBV Near Deal for $RVMD. $VSTM sympathy play. https://t.co/3kV0WivXQs https://t.co/X8Gqg92jSG"
X Link 2026-01-07T20:06Z [----] followers, [----] engagements
"$AMLX Announces Nomination of AMX0318 as a Novel Long-Acting GLP-1 Receptor Antagonist Development Candidate Identified in Collaboration with $GUBRA. #Obesity https://www.businesswire.com/news/home/20260108102624/en/Amylyx-Pharmaceuticals-Announces-Nomination-of-AMX0318-as-a-Novel-Long-Acting-GLP-1-Receptor-Antagonist-Development-Candidate-Identified-in-Collaboration-with-Gubra-AS"
X Link 2026-01-08T12:01Z [----] followers, [---] engagements
"$IVVD Reports Preliminary Fourth Quarter [----] Revenue and Recent Business Highlights. Preliminary Q4 [----] PEMGARDA (pemivibart) net product revenue of $17.2 million. https://www.globenewswire.com/news-release/2026/01/08/3215229/0/en/Invivyd-Reports-Preliminary-Fourth-Quarter-2025-Revenue-and-Recent-Business-Highlights.html_gl=1*v0qjys*_up*MQ.*_ga*MTM0ODg5ODE3Ni4xNzY3ODczNzcx*_ga_ERWPGTJ5X8*czE3Njc4NzM3NzAkbzEkZzAkdDE3Njc4NzM3NzIkajU4JGwwJGgw"
X Link 2026-01-08T12:03Z [----] followers, [----] engagements
"$ZEAL enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier [----] strategy https://www.globenewswire.com/news-release/2026/01/09/3215901/0/en/Zealand-Pharma-enters-agreement-with-DCAI-to-use-Gefion-AI-supercomputer-to-accelerate-drug-discovery-and-support-Metabolic-Frontier-2030-strategy.html_gl=1*1ih08un*_up*MQ.*_ga*MTE4MzAyMjk2My4xNzY3OTQyMTY3*_ga_ERWPGTJ5X8*czE3Njc5NDIxNjYkbzEkZzAkdDE3Njc5NDIxNjgkajU4JGwwJGgw"
X Link 2026-01-09T07:03Z [----] followers, [---] engagements
"$SDGR Partners with $LLY to Make TuneLab Platform Available in LiveDesign https://www.businesswire.com/news/home/20260109308931/en/Schrdinger-Partners-with-Lilly-to-Make-TuneLab-Platform-Available-in-LiveDesign https://www.businesswire.com/news/home/20260109308931/en/Schrdinger-Partners-with-Lilly-to-Make-TuneLab-Platform-Available-in-LiveDesign"
X Link 2026-01-09T12:01Z [----] followers, [----] engagements
"$NAMS Highlights [----] Achievements and Outlines [----] Strategic Priorities https://www.globenewswire.com/news-release/2026/01/09/3216046/0/en/NewAmsterdam-Pharma-Highlights-2025-Achievements-and-Outlines-2026-Strategic-Priorities.html_gl=1*32yk4*_up*MQ.*_ga*MTk5NDI0MTExMy4xNzY3OTU4MzIx*_ga_ERWPGTJ5X8*czE3Njc5NjM4NTMkbzIkZzAkdDE3Njc5NjM4NTMkajYwJGwwJGgw"
X Link 2026-01-09T13:04Z [----] followers, [----] engagements
"$DCTH Announces Preliminary Fourth Quarter and Full Year [----] Financial Results https://www.businesswire.com/news/home/20260109101869/en/Delcath-Systems-Announces-Preliminary-Fourth-Quarter-and-Full-Year-2025-Financial-Results https://www.businesswire.com/news/home/20260109101869/en/Delcath-Systems-Announces-Preliminary-Fourth-Quarter-and-Full-Year-2025-Financial-Results"
X Link 2026-01-09T13:06Z [----] followers, [---] engagements
"$RGNX Highlights Key [----] Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program https://www.prnewswire.com/news-releases/regenxbio-highlights-key-2026-catalysts-and-announces-positive-long-term-functional-outcomes-in-lead-duchenne-gene-therapy-program-302657988.html https://www.prnewswire.com/news-releases/regenxbio-highlights-key-2026-catalysts-and-announces-positive-long-term-functional-outcomes-in-lead-duchenne-gene-therapy-program-302657988.html"
X Link 2026-01-11T20:23Z [----] followers, [----] engagements
"$MBX to Provide [----] Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference https://www.globenewswire.com/news-release/2026/01/11/3216493/0/en/MBX-Biosciences-to-Provide-2026-Outlook-and-Business-Update-at-44th-Annual-J-P-Morgan-Healthcare-Conference.html_gl=1*91pgy4*_up*MQ.*_ga*MTYzNDUzMDMwLjE3NjgxNjUzMDM.*_ga_ERWPGTJ5X8*czE3NjgxNjUzMDIkbzEkZzAkdDE3NjgxNjUzMDIkajYwJGwwJGgw"
X Link 2026-01-11T21:02Z [----] followers, [----] engagements
"$EXEL Announces Preliminary Fiscal Year [----] Financial Results Provides [----] Financial Guidance and Outlines Key Priorities and Milestones for [----] https://www.businesswire.com/news/home/20260111609689/en/Exelixis-Announces-Preliminary-Fiscal-Year-2025-Financial-Results-Provides-2026-Financial-Guidance-and-Outlines-Key-Priorities-and-Milestones-for-2026 https://www.businesswire.com/news/home/20260111609689/en/Exelixis-Announces-Preliminary-Fiscal-Year-2025-Financial-Results-Provides-2026-Financial-Guidance-and-Outlines-Key-Priorities-and-Milestones-for-2026"
X Link 2026-01-11T21:03Z [----] followers, [----] engagements
"$BEAM Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition https://www.globenewswire.com/news-release/2026/01/11/3216497/0/en/Beam-Therapeutics-Sets-Strategic-Priorities-for-its-Genetic-Disease-and-Hematology-Franchises-to-Drive-Execution-of-Late-Stage-Clinical-Programs-and-Extends-its-Operating-Runway-th.html_gl=1*3jlhcr*_up*MQ.*_ga*MTgwMzg5MDQwMi4xNzY4MTY4OTMw*_ga_ERWPGTJ5X8*czE3NjgxNjg5MzAkbzEkZzAkdDE3NjgxNjg5MzAkajYwJGwwJGgw"
X Link 2026-01-11T22:04Z [----] followers, [----] engagements
"$ALNY Launches Alnylam [----] Strategy to Drive Next Era of Growth and Patient Impact https://www.businesswire.com/news/home/20260111699710/en/Alnylam-Launches-Alnylam-2030-Strategy-to-Drive-Next-Era-of-Growth-and-Patient-Impact https://www.businesswire.com/news/home/20260111699710/en/Alnylam-Launches-Alnylam-2030-Strategy-to-Drive-Next-Era-of-Growth-and-Patient-Impact"
X Link 2026-01-11T22:07Z [----] followers, [----] engagements
"$QGEN #Qiagen Sets [----] Priorities to Drive Growth Across Five Pillars Toward Achieving [----] Goals for Solid Profitable Growth https://www.businesswire.com/news/home/20260111774770/en/QIAGEN-Sets-2026-Priorities-to-Drive-Growth-Across-Five-Pillars-Toward-Achieving-2028-Goals-for-Solid-Profitable-Growth https://www.businesswire.com/news/home/20260111774770/en/QIAGEN-Sets-2026-Priorities-to-Drive-Growth-Across-Five-Pillars-Toward-Achieving-2028-Goals-for-Solid-Profitable-Growth"
X Link 2026-01-12T07:02Z [----] followers, [----] engagements
"$NRIX Outlines [----] Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases https://www.globenewswire.com/news-release/2026/01/12/3216702/0/en/Nurix-Therapeutics-Outlines-2026-Goals-and-Objectives-for-Advancing-Bexobrutideg-and-Its-Pipeline-of-Novel-Degrader-Based-Medicines-in-Cancer-and-Autoimmune-Diseases.html_gl=1*lw91wk*_up*MQ.*_ga*NDc4Mzg0NDk4LjE3NjgyMTkzODY.*_ga_ERWPGTJ5X8*czE3NjgyMTkzODYkbzEkZzAkdDE3NjgyMTkzODYkajYwJGwwJGgw"
X Link 2026-01-12T12:03Z [----] followers, [---] engagements
"$AXSM Provides Preliminary Fourth Quarter and Full Year [----] Net Product Revenue https://www.globenewswire.com/news-release/2026/01/12/3216700/33090/en/Axsome-Therapeutics-Provides-Preliminary-Fourth-Quarter-and-Full-Year-2025-Net-Product-Revenue.html_gl=1*scdgei*_up*MQ.*_ga*NDc4Mzg0NDk4LjE3NjgyMTkzODY.*_ga_ERWPGTJ5X8*czE3NjgyMTkzODYkbzEkZzAkdDE3NjgyMTk0MzIkajE0JGwwJGgw"
X Link 2026-01-12T12:04Z [----] followers, [----] engagements
"$KYTX Provides Corporate Update and Outlines [----] Strategic Priorities at the J.P. Morgan Healthcare Conference https://www.globenewswire.com/news-release/2026/01/12/3216812/0/en/Kyverna-Therapeutics-Provides-Corporate-Update-and-Outlines-2026-Strategic-Priorities-at-the-J-P-Morgan-Healthcare-Conference.html_gl=1*b4hgv8*_up*MQ.*_ga*MzQ1MTg0MjY2LjE3NjgyMjI1NTQ.*_ga_ERWPGTJ5X8*czE3NjgyMjI1NTQkbzEkZzAkdDE3NjgyMjMwNDMkajE1JGwwJGgw"
X Link 2026-01-12T13:04Z [----] followers, [----] engagements
"$PRAX Enters Its Next Chapter Following a Pivotal Year of Progress https://www.globenewswire.com/news-release/2026/01/12/3216856/0/en/Praxis-Precision-Medicines-Enters-Its-Next-Chapter-Following-a-Pivotal-Year-of-Progress.html_gl=1*1i2vn53*_up*MQ.*_ga*MzQ1MTg0MjY2LjE3NjgyMjI1NTQ.*_ga_ERWPGTJ5X8*czE3NjgyMjI1NTQkbzEkZzAkdDE3NjgyMjMwNjgkajYwJGwwJGgw"
X Link 2026-01-12T13:04Z [----] followers, [----] engagements
"$BIOA Announces Additional Positive Interim Phase [--] Data for BGE-102 a Novel Brain-Penetrant #NLRP3 Inhibitor Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk. $VTYX $LLY $NMRA"
X Link 2026-01-12T14:04Z [----] followers, [----] engagements
"$BIOA new high $LLY $VTYX #NLRP3 $BIOA Announces Additional Positive Interim Phase [--] Data for BGE-102 a Novel Brain-Penetrant #NLRP3 Inhibitor Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk. $VTYX $LLY $NMRA https://t.co/bitUfbV1rd $BIOA Announces Additional Positive Interim Phase [--] Data for BGE-102 a Novel Brain-Penetrant #NLRP3 Inhibitor Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk. $VTYX $LLY $NMRA https://t.co/bitUfbV1rd"
X Link 2026-01-12T14:41Z [----] followers, [----] engagements
"$BIOA BGE-102 with best-in-class efficacy New slides out. It is becoming increasingly apparent that NLRP3 could be a target for a broad spectrum of therapeutic applications. #Longevity $VTYX $LLY https://ir.bioagelabs.com/static-files/85d8c598-5048-42cd-9f64-6842b1433ac1 https://ir.bioagelabs.com/static-files/85d8c598-5048-42cd-9f64-6842b1433ac1"
X Link 2026-01-13T06:58Z [----] followers, [----] engagements
"$ONC Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference https://www.businesswire.com/news/home/20260113426214/en/BeOne-Medicines-Highlights-Global-Oncology-Leadership-at-44th-Annual-J.P.-Morgan-Healthcare-Conference https://www.businesswire.com/news/home/20260113426214/en/BeOne-Medicines-Highlights-Global-Oncology-Leadership-at-44th-Annual-J.P.-Morgan-Healthcare-Conference"
X Link 2026-01-13T11:02Z [----] followers, [----] engagements
"Sold $MLTX starter $DAWN"
X Link 2026-01-13T14:46Z [----] followers, 12.4K engagements
"TOXINS 2026: Clinical Updates on $GALD #Galdermas Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics https://www.businesswire.com/news/home/20260113854672/en/TOXINS-2026-Clinical-Updates-on-Galdermas-Leading-Neuromodulator-Portfolio-Further-Reinforce-Its-Leadership-in-Injectable-Aesthetics https://www.businesswire.com/news/home/20260113854672/en/TOXINS-2026-Clinical-Updates-on-Galdermas-Leading-Neuromodulator-Portfolio-Further-Reinforce-Its-Leadership-in-Injectable-Aesthetics"
X Link 2026-01-14T06:32Z [----] followers, [----] engagements
"JPM26: $PFE $MTSR deal supercharges its obesity strategy. $NVO $LLY $VKTX https://finance.yahoo.com/news/jpm26-pfizer-metsera-deal-supercharges-195036915.html https://finance.yahoo.com/news/jpm26-pfizer-metsera-deal-supercharges-195036915.html"
X Link 2026-01-14T07:39Z [----] followers, [----] engagements
"$CCCC Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways https://www.globenewswire.com/news-release/2026/01/14/3218491/0/en/C4-Therapeutics-Outlines-Strategic-Milestones-to-Advance-Cemsidomide-as-a-Potential-Best-in-Class-IKZF1-3-Degrader-and-Discovery-Strategy-Focused-on-Novel-Targets-in-Clinically-Val.html_gl=1*1ktonar*_up*MQ.*_ga*MTcyOTIxODY1NC4xNzY4MzkyMTE5*_ga_ERWPGTJ5X8*czE3NjgzOTIxMTkkbzEkZzAkdDE3NjgzOTIxMjgkajUxJGwwJGgw"
X Link 2026-01-14T12:02Z [----] followers, [----] engagements
"$SNY Myqorzo and Redemplo approved in China. $CYTK $ARWR https://www.globenewswire.com/news-release/2026/01/15/3219227/0/en/Press-Release-Myqorzo-and-Redemplo-approved-in-China.html https://www.globenewswire.com/news-release/2026/01/15/3219227/0/en/Press-Release-Myqorzo-and-Redemplo-approved-in-China.html"
X Link 2026-01-15T06:04Z [----] followers, [----] engagements
"#LaLettre: $SNY makes fresh play for $OCUL. The French pharmaceutical group and its chief executive Paul Hudson are preparing an improved bid to acquire the US biotech start-up. Its initial offer of$16 per share was rejected by the US biotech's board. https://www.lalettre.fr/fr/entreprises_sante/2026/01/15/sanofi-makes-fresh-play-for-ocular-therapeutix110601305-fac https://www.lalettre.fr/fr/entreprises_sante/2026/01/15/sanofi-makes-fresh-play-for-ocular-therapeutix110601305-fac"
X Link 2026-01-15T07:28Z [----] followers, 25.4K engagements
"$IMCR One of the more interesting science experiments going on. Some may remember Pandion had some early programs like this. PD1 agonist (like Peresolimab Rosnilimab) but tissue tethered. Here beta cells of T1D patients. Idea is cause T-cell exhaustion locally. https://t.co/FFd4obel54 One of the more interesting science experiments going on. Some may remember Pandion had some early programs like this. PD1 agonist (like Peresolimab Rosnilimab) but tissue tethered. Here beta cells of T1D patients. Idea is cause T-cell exhaustion locally. https://t.co/FFd4obel54"
X Link 2026-01-15T11:14Z [----] followers, [----] engagements
"$IRON $SNY $LLY cc $NVO US FDA delays two drug reviews in new voucher program after safety efficacy concerns. Two other drugs tapped for the speedy review program have also been pushed by weeks or longer beyond the original target date. A decision on Boehringer Ingelheim's zongertinib for lung cancer is currently expected mid-February and $LLY weight-loss pill is now due April [--] according to documents. https://ca.news.yahoo.com/exclusive-us-fda-delays-two-110222936.html https://ca.news.yahoo.com/exclusive-us-fda-delays-two-110222936.html"
X Link 2026-01-15T11:18Z [----] followers, 12.6K engagements
"Brenig Therapeutics Announces Initiation of First-in-Human Study of BT-409 a Brain-Selective NLRP3 Inhibitor and Provides Update on BT-267 its LRRK2 Program. $BIOA $NMRA $VTYX $LLY https://www.prnewswire.com/news-releases/brenig-therapeutics-announces-initiation-of-first-in-human-study-of-bt-409-a-brain-selective-nlrp3-inhibitor-and-provides-update-on-bt-267-its-lrrk2-program-302662068.html"
X Link 2026-01-15T12:01Z [----] followers, [----] engagements
"$TERN looking good"
X Link 2026-01-16T17:00Z [----] followers, [----] engagements
"$GMAB Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase [--] EPCORE DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) https://www.globenewswire.com/news-release/2026/01/16/3220513/0/en/Genmab-Announces-Topline-Results-for-Epcoritamab-DuoBody-CD3xCD20-from-Phase-3-EPCORE-DLBCL-1-Trial-in-Patients-with-Relapsed-Refractory-Diffuse-Large-B-cell-Lymphoma-DLBCL.html"
X Link 2026-01-16T18:37Z [----] followers, [----] engagements
"$GH Announces Multi-Year Strategic Collaboration Agreement with $MRK to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform https://investors.guardanthealth.com/press-releases/press-releases/2026/Guardant-Health-Announces-Multi-Year-Strategic-Collaboration-Agreement-with-Merck-to-Develop-Companion-Diagnostics-and-Commercialize-New-Cancer-Therapies-Using-Guardant-Infinity-Smart-Platform/default.aspx"
X Link 2026-01-19T14:55Z [----] followers, [----] engagements
"#InsilicoMedicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment. $BIOA $NMRA $VTYX $LLY https://insilico.com/news/r6iax95rk1-insilico-medicine-and-hygtia-therapeutic https://insilico.com/news/r6iax95rk1-insilico-medicine-and-hygtia-therapeutic"
X Link 2026-01-20T08:13Z [----] followers, [----] engagements
"$BOLD halted"
X Link 2026-01-20T11:56Z [----] followers, [----] engagements
"$BOLD Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway https://investors.boundlessbio.com/news-releases/news-release-details/boundless-bio-advances-novel-kinesin-degrader-program-bbi-940 $BOLD halted https://investors.boundlessbio.com/news-releases/news-release-details/boundless-bio-advances-novel-kinesin-degrader-program-bbi-940 $BOLD halted"
X Link 2026-01-20T12:02Z [----] followers, [----] engagements
"$CRVS Announces Positive Data from Cohort [--] Confirming Results for Placebo-Controlled Phase [--] Clinical Trial of Soquelitinib for Atopic Dermatitis. $NKTR $KYMR $SNY $AMGN https://investor.corvuspharma.com/news-releases/news-release-details/corvus-pharmaceuticals-announces-positive-data-cohort-4 https://investor.corvuspharma.com/news-releases/news-release-details/corvus-pharmaceuticals-announces-positive-data-cohort-4"
X Link 2026-01-20T12:11Z [----] followers, [----] engagements
"$DYN Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type [--] https://www.globenewswire.com/news-release/2026/01/20/3221596/0/en/Dyne-Therapeutics-Receives-Orphan-Drug-Designation-in-Japan-for-Zeleciment-Basivarsen-DYNE-101-for-Myotonic-Dystrophy-Type-1.html https://www.globenewswire.com/news-release/2026/01/20/3221596/0/en/Dyne-Therapeutics-Receives-Orphan-Drug-Designation-in-Japan-for-Zeleciment-Basivarsen-DYNE-101-for-Myotonic-Dystrophy-Type-1.html"
X Link 2026-01-20T12:31Z [----] followers, [---] engagements
"$BIOA Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102 with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026. $VTYX $LLY $NMRA https://www.globenewswire.com/news-release/2026/01/20/3221761/0/en/BioAge-Announces-Indication-Expansion-for-Oral-NLRP3-Inhibitor-BGE-102-with-Plans-to-Initiate-Phase-1b-2a-Proof-of-Concept-Clinical-Trial-in-Patients-with-Diabetic-Macular-Edema-in.html"
X Link 2026-01-20T14:01Z [----] followers, [----] engagements
"$BIOA new corporate presentation out. The company now wants to enter the field of ophthalmology (diabetic macular edema) with BGE-102 (NLRP3 inhibitor). Exciting. #Longevity $LLY $VTYX $NMRA https://ir.bioagelabs.com/static-files/85d8c598-5048-42cd-9f64-6842b1433ac1 $BIOA Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102 with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026. $VTYX $LLY $NMRA https://t.co/DhtnzpzKY8 https://ir.bioagelabs.com/static-files/85d8c598-5048-42cd-9f64-6842b1433ac1 $BIOA Announces"
X Link 2026-01-20T14:09Z [----] followers, [----] engagements
"What a day for $DAWN yesterday. Delayed price reaction to strong prelim. Ojemda Q4 sales. From a technical perspective the signs are very good and the short ratio is high. Indication expansions could spark further growth and ADCs are hot. Takeover speculation is re-emerging. Sold $MLTX starter $DAWN Sold $MLTX starter $DAWN"
X Link 2026-01-21T06:32Z [----] followers, 12.6K engagements
"$BIOA offering. I expect high demand NLRP3 has high therapeutic potential in many areas BioAge underscores this with its move into ophthalmology. The acquisition of $VTYX by $LLY is an additional investment trigger. https://ir.bioagelabs.com/news-releases/news-release-details/bioage-announces-proposed-public-offering https://ir.bioagelabs.com/news-releases/news-release-details/bioage-announces-proposed-public-offering"
X Link 2026-01-21T08:09Z [----] followers, [----] engagements
"$DAWN $13 up 7% - investment case below 👇👌 What a day for $DAWN yesterday. Delayed price reaction to strong prelim. Ojemda Q4 sales. From a technical perspective the signs are very good and the short ratio is high. Indication expansions could spark further growth and ADCs are hot. Takeover speculation is re-emerging. https://t.co/yltzqewWv7 What a day for $DAWN yesterday. Delayed price reaction to strong prelim. Ojemda Q4 sales. From a technical perspective the signs are very good and the short ratio is high. Indication expansions could spark further growth and ADCs are hot. Takeover"
X Link 2026-01-21T14:44Z [----] followers, [----] engagements
"$BIOA Announces Pricing of Upsized $115.0 Million Public Offering - $19.50 per share. Really strong offering shares closed at $20.12 yestarday https://www.globenewswire.com/news-release/2026/01/22/3223360/0/en/BioAge-Announces-Pricing-of-Upsized-115-0-Million-Public-Offering.html https://www.globenewswire.com/news-release/2026/01/22/3223360/0/en/BioAge-Announces-Pricing-of-Upsized-115-0-Million-Public-Offering.html"
X Link 2026-01-22T05:52Z [----] followers, [----] engagements
"PD1xVEGF = 🔥 $SMMT #Akeso $BNTX $BMY $PFE #3SBio $MRK #LaNova $CBIO PD1xVEGF programs from Guggenheim's report on $CBIO https://t.co/FJ7XkbUheW PD1xVEGF programs from Guggenheim's report on $CBIO https://t.co/FJ7XkbUheW"
X Link 2026-01-22T10:23Z [----] followers, [----] engagements
"Long $NVO $NOVOB #NovoNordisk #Novo Kepler calls 2nd week oral semaglutide prescription data "stellar" "Hitting 20k Rx in its second week is pointing way above even our top-of-consensus forecasts. We think consensus had been modelling perhaps only 1.5k Rx being added each week. We had modelled more like 5k #Novo Kepler calls 2nd week oral semaglutide prescription data "stellar" "Hitting 20k Rx in its second week is pointing way above even our top-of-consensus forecasts. We think consensus had been modelling perhaps only 1.5k Rx being added each week. We had modelled more like 5k"
X Link 2026-01-23T07:34Z [----] followers, [----] engagements
"$BIIB FDA Accepts LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early #Alzheimers Disease under Priority Review https://investors.biogen.com/news-releases/news-release-details/fda-accepts-leqembir-iqliktm-lecanemab-irmb-supplemental https://investors.biogen.com/news-releases/news-release-details/fda-accepts-leqembir-iqliktm-lecanemab-irmb-supplemental"
X Link 2026-01-26T10:46Z [----] followers, [----] engagements
"$UTHR Announces Positive Results from Phase [--] Study of miroliverELAP in Patients with Acute Liver Failure https://www.businesswire.com/news/home/20260126667812/en/United-Therapeutics-Announces-Positive-Results-from-Phase-1-Study-of-miroliverELAP-in-Patients-with-Acute-Liver-Failure https://www.businesswire.com/news/home/20260126667812/en/United-Therapeutics-Announces-Positive-Results-from-Phase-1-Study-of-miroliverELAP-in-Patients-with-Acute-Liver-Failure"
X Link 2026-01-26T12:19Z [----] followers, [----] engagements
"$RHHBY Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity. $LLY $NVO $VKTX https://www.globenewswire.com/news-release/2026/01/27/3226074/0/en/Ad-hoc-announcement-pursuant-to-Art-53-LR-Roche-announces-positive-Phase-II-results-for-its-dual-GLP-1-GIP-receptor-agonist-CT-388-in-people-living-with-obesity.html"
X Link 2026-01-27T06:04Z [----] followers, [----] engagements
"$ARWR Initiates Phase 1/2a Study of ARO-DIMER-PA the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia https://www.businesswire.com/news/home/20260127479152/en/Arrowhead-Pharmaceuticals-Initiates-Phase-12a-Study-of-ARO-DIMER-PA-the-First-Dual-Functional-RNAi-Therapeutic-for-the-Treatment-of-Mixed-Hyperlipidemia https://www.businesswire.com/news/home/20260127479152/en/Arrowhead-Pharmaceuticals-Initiates-Phase-12a-Study-of-ARO-DIMER-PA-the-First-Dual-Functional-RNAi-Therapeutic-for-the-Treatment-of-Mixed-Hyperlipidemia"
X Link 2026-01-27T13:07Z [----] followers, [----] engagements
"#Boehringer Ingelheims investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial. $TVTX $VRTX https://www.globenewswire.com/news-release/2026/01/28/3227186/0/en/Boehringer-Ingelheim-s-investigational-asset-apecotrep-delivers-proteinuria-reduction-in-Phase-II-kidney-trial.html https://www.globenewswire.com/news-release/2026/01/28/3227186/0/en/Boehringer-Ingelheim-s-investigational-asset-apecotrep-delivers-proteinuria-reduction-in-Phase-II-kidney-trial.html"
X Link 2026-01-28T06:15Z [----] followers, [----] engagements
"$TEVA innovative pipeline potential duvakitug (anti-TL1A) in UC/CD $5B estimated peak sales in a $38B market. UC/CD Phase [--] maintenance data: H126. #IBD $SNY cc: $ABVX https://ir.tevapharm.com/Events-and-Presentations/events-and-presentations/default.aspx https://ir.tevapharm.com/Events-and-Presentations/events-and-presentations/default.aspx"
X Link 2026-01-28T12:26Z [----] followers, [----] engagements
"$BIIB Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus a Disease With No Targeted Treatment Options https://www.globenewswire.com/news-release/2026/01/28/3227517/0/en/Biogen-s-Litifilimab-Receives-FDA-Breakthrough-Therapy-Designation-for-Cutaneous-Lupus-Erythematosus-a-Disease-With-No-Targeted-Treatment-Options.html https://www.globenewswire.com/news-release/2026/01/28/3227517/0/en/Biogen-s-Litifilimab-Receives-FDA-Breakthrough-Therapy-Designation-for-Cutaneous-Lupus-Erythematosus-a-Disease-With-No-Targeted-Treatment-Options.html"
X Link 2026-01-28T12:31Z [----] followers, [----] engagements
"$RGNX clinical holds https://www.prnewswire.com/news-releases/regenxbio-announces-regulatory-update-on-ultra-rare-mps-programs-302672061.html https://www.prnewswire.com/news-releases/regenxbio-announces-regulatory-update-on-ultra-rare-mps-programs-302672061.html"
X Link 2026-01-28T12:32Z [----] followers, [----] engagements
"$CAI Real-World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab Deruxtecan https://www.prnewswire.com/news-releases/caris-life-sciences-real-world-data-uncovers-metastatic-breast-cancer-patient-responses-and-resistance-to-trastuzumab-deruxtecan-302672228.html https://www.prnewswire.com/news-releases/caris-life-sciences-real-world-data-uncovers-metastatic-breast-cancer-patient-responses-and-resistance-to-trastuzumab-deruxtecan-302672228.html"
X Link 2026-01-28T13:32Z [----] followers, [----] engagements
"$DAWN bullish. Interesting potential bolt-on acquisition target story below. $MRSN What a day for $DAWN yesterday. Delayed price reaction to strong prelim. Ojemda Q4 sales. From a technical perspective the signs are very good and the short ratio is high. Indication expansions could spark further growth and ADCs are hot. Takeover speculation is re-emerging. https://t.co/yltzqewWv7 What a day for $DAWN yesterday. Delayed price reaction to strong prelim. Ojemda Q4 sales. From a technical perspective the signs are very good and the short ratio is high. Indication expansions could spark further"
X Link 2026-01-28T14:36Z [----] followers, [----] engagements
"$RHHBY #Roche reports strong [----] results with 7% sales growth https://www.globenewswire.com/news-release/2026/01/29/3228176/0/en/Ad-hoc-announcement-pursuant-to-Art-53-LR-Roche-reports-strong-2025-results-with-7-sales-growth.html https://www.globenewswire.com/news-release/2026/01/29/3228176/0/en/Ad-hoc-announcement-pursuant-to-Art-53-LR-Roche-reports-strong-2025-results-with-7-sales-growth.html"
X Link 2026-01-29T06:31Z [----] followers, [----] engagements
"#Akeso $SMMT Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026" https://www.prnewswire.com/news-releases/ivonescimab-included-in-firstword-pharmas-the-drugs-that-will-shape-2026-302673512.html https://www.prnewswire.com/news-releases/ivonescimab-included-in-firstword-pharmas-the-drugs-that-will-shape-2026-302673512.html"
X Link 2026-01-29T06:33Z [----] followers, [----] engagements
"$SNY $REGN #Dupixent growth is just impressive. $CRVS $NKTR $KYMR"
X Link 2026-01-29T06:36Z [----] followers, [----] engagements
"$SNY more M&A firepower"
X Link 2026-01-29T06:37Z [----] followers, [----] engagements
"$MRK veteran Perlmutter-led Eikon Therapeutics eyes $908 million valuation in IPO. $EIKN #Keytruda https://www.reuters.com/business/healthcare-pharmaceuticals/eikon-therapeutics-targets-908-million-valuation-us-ipo-2026-01-28/ https://www.reuters.com/business/healthcare-pharmaceuticals/eikon-therapeutics-targets-908-million-valuation-us-ipo-2026-01-28/"
X Link 2026-01-29T09:21Z [----] followers, [----] engagements
"$GUTS Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita After GLP-1 Discontinuation https://www.globenewswire.com/news-release/2026/01/29/3228413/0/en/Fractyl-Health-Announces-Compelling-6-Month-Randomized-REMAIN-1-Midpoint-Data-Showing-Durable-Weight-Maintenance-with-Revita-After-GLP-1-Discontinuation.html https://www.globenewswire.com/news-release/2026/01/29/3228413/0/en/Fractyl-Health-Announces-Compelling-6-Month-Randomized-REMAIN-1-Midpoint-Data-Showing-Durable-Weight-Maintenance-with-Revita-After-GLP-1-Discontinuation.html"
X Link 2026-01-29T12:14Z [----] followers, [----] engagements
"$KYMR Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621 a First-in-Class Oral STAT6 Degrader https://www.globenewswire.com/news-release/2026/01/29/3228409/0/en/Kymera-Therapeutics-Announces-First-Patient-Dosed-in-BREADTH-Phase-2b-Asthma-Clinical-Trial-of-KT-621-a-First-in-Class-Oral-STAT6-Degrader.html https://www.globenewswire.com/news-release/2026/01/29/3228409/0/en/Kymera-Therapeutics-Announces-First-Patient-Dosed-in-BREADTH-Phase-2b-Asthma-Clinical-Trial-of-KT-621-a-First-in-Class-Oral-STAT6-Degrader.html"
X Link 2026-01-29T12:14Z [----] followers, [----] engagements
"China's CSPC Pharmaceutical signs deal with $AZN for weight-loss therapy. $1.2B upfront. $NVO $LLY $VKTX https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-cspc-pharmaceutical-inks-deal-with-astrazeneca-weight-loss-therapy-2026-01-30/ https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-cspc-pharmaceutical-inks-deal-with-astrazeneca-weight-loss-therapy-2026-01-30/"
X Link 2026-01-30T06:12Z [----] followers, [----] engagements
"$GRAL Submits FDA Premarket Approval Application for the Galleri Multi-Cancer Early Detection Test https://grail.com/press-releases/grail-submits-fda-premarket-approval-application-for-the-galleri-multi-cancer-early-detection-test/ https://grail.com/press-releases/grail-submits-fda-premarket-approval-application-for-the-galleri-multi-cancer-early-detection-test/"
X Link 2026-01-30T06:50Z [----] followers, [----] engagements
"$AMGN acquired Tavneos through the acquisition of $CCXI for $4B back in August [----]. $IFRX https://www.amgen.com/newsroom/press-releases/2022/08/amgen-to-acquire-chemocentryx-for-$4-billion-in-cash What's this about EMA re-reviewing $AMGN Tavneos due to "data integrity" issues in study that supported approval. https://t.co/lg9eh7qSmJ https://www.amgen.com/newsroom/press-releases/2022/08/amgen-to-acquire-chemocentryx-for-$4-billion-in-cash What's this about EMA re-reviewing $AMGN Tavneos due to "data integrity" issues in study that supported approval. https://t.co/lg9eh7qSmJ"
X Link 2026-01-30T12:57Z [----] followers, [----] engagements
"$TERN @zohmbastic"
X Link 2026-01-30T14:55Z [----] followers, [----] engagements
"$TERN volume 👀 $TERN small vol spreads https://t.co/kn05raTH6t $TERN small vol spreads https://t.co/kn05raTH6t"
X Link 2026-01-30T18:38Z [----] followers, [----] engagements
"It seems that there are some M&A speculations surrounding $TERN. 👍 TERN-701 could be another AML blockbuster. Would not be surprised if $MRK is interested. $RVMD @seedy19tron Saw this on $TERN last week. Obvious thought was clearing the way for partnerships but maybe it is actually clearing the way for an M&A 🤔 https://t.co/iCFrBx8G9Z @seedy19tron Saw this on $TERN last week. Obvious thought was clearing the way for partnerships but maybe it is actually clearing the way for an M&A 🤔 https://t.co/iCFrBx8G9Z"
X Link 2026-01-30T19:34Z [----] followers, [----] engagements
"It seems that there are some M&A speculations surrounding $TERN. 👍 TERN-701 could be another CML blockbuster. Would not be surprised if $MRK is interested. $RVMD @seedy19tron Saw this on $TERN last week. Obvious thought was clearing the way for partnerships but maybe it is actually clearing the way for an M&A 🤔 https://t.co/iCFrBx8G9Z @seedy19tron Saw this on $TERN last week. Obvious thought was clearing the way for partnerships but maybe it is actually clearing the way for an M&A 🤔 https://t.co/iCFrBx8G9Z"
X Link 2026-01-30T19:40Z [----] followers, [----] engagements
"From December: [--] Biotechs That Could Be Big Pharmas Next M&A Target. $VTYX gone Next $TERN $VKTX $GPCR $ABVX or $MPLT https://www.biospace.com/business/6-biotechs-that-could-be-big-pharmas-next-m-a-target https://www.biospace.com/business/6-biotechs-that-could-be-big-pharmas-next-m-a-target"
X Link 2026-01-31T12:58Z [----] followers, 14.2K engagements
"$SNY venglustat met all primary endpoints in a phase [--] study of type [--] Gaucher disease https://www.globenewswire.com/news-release/2026/02/02/3229947/0/en/Press-Release-Sanofi-s-venglustat-met-all-primary-endpoints-in-a-phase-3-study-of-type-3-Gaucher-disease.html https://www.globenewswire.com/news-release/2026/02/02/3229947/0/en/Press-Release-Sanofi-s-venglustat-met-all-primary-endpoints-in-a-phase-3-study-of-type-3-Gaucher-disease.html"
X Link 2026-02-02T06:06Z [----] followers, [----] engagements
"$GALD #Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission https://www.businesswire.com/news/home/20260201157212/en/Galderma-Announces-U.S.-FDA-Acceptance-of-RelabotulinumtoxinA-Biologics-License-Application-Resubmission https://www.businesswire.com/news/home/20260201157212/en/Galderma-Announces-U.S.-FDA-Acceptance-of-RelabotulinumtoxinA-Biologics-License-Application-Resubmission"
X Link 2026-02-02T06:07Z [----] followers, [----] engagements
"Interesting thesis - nevertheless there could be more than one potential suitor for $TERN. $MRK $ABBV and $NVS would make sense here. Just a phase 1b asset but if Terns confirm the potential in a larger late-stage trial $3B + x peak sales is not unrealistic. #Scemblix The recent $TERN developments are really interesting. Novartis has a history of buying out the competition and stark parallels can be made to MorphoSys acquisition. That was to protect Jakavi SOC in myelofibrosis same as TERN-701 would protect Scemblix $5B revenue stream in CML The recent $TERN developments are really"
X Link 2026-02-02T07:25Z [----] followers, [----] engagements
"OX40 programs with an uncertain future after mixed results and the termination of the rocatinlimab collab. with Kyowa Kirin by $AMGN. $NKTR CBO told me in Nov. that an early evidence of efficacy is important for treatment adherence in practice. $CRVS $SNY https://www.deraktionaer.de/artikel/pharma-biotech/nektar-therapeutics-marktpotenzial-in-milliardenhoehe-cbo-im-exklusivinterview-teil-2-20391215.html https://www.deraktionaer.de/artikel/pharma-biotech/nektar-therapeutics-marktpotenzial-in-milliardenhoehe-cbo-im-exklusivinterview-teil-2-20391215.html"
X Link 2026-02-02T08:57Z [----] followers, [----] engagements
"$TWST Fiscal [----] First Quarter Financial Results https://www.businesswire.com/news/home/20260202309201/en/Twist-Bioscience-Announces-Fiscal-2026-First-Quarter-Financial-Results https://www.businesswire.com/news/home/20260202309201/en/Twist-Bioscience-Announces-Fiscal-2026-First-Quarter-Financial-Results"
X Link 2026-02-02T12:23Z [----] followers, [----] engagements
"$WVE Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency https://www.globenewswire.com/news-release/2026/02/02/3230159/0/en/Wave-Life-Sciences-Announces-Plans-to-Accelerate-Regulatory-Engagement-with-Full-Control-of-WVE-006-for-Alpha-1-Antitrypsin-Deficiency.html https://www.globenewswire.com/news-release/2026/02/02/3230159/0/en/Wave-Life-Sciences-Announces-Plans-to-Accelerate-Regulatory-Engagement-with-Full-Control-of-WVE-006-for-Alpha-1-Antitrypsin-Deficiency.html"
X Link 2026-02-02T12:31Z [----] followers, [----] engagements
"$MLTX Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day https://www.globenewswire.com/news-release/2026/02/02/3230183/0/en/MoonLake-Announces-FDA-Fast-Track-Designation-for-Sonelokimab-Palmoplantar-Pustulosis-PPP-and-Provides-Details-on-Upcoming-Investor-Day.html https://www.globenewswire.com/news-release/2026/02/02/3230183/0/en/MoonLake-Announces-FDA-Fast-Track-Designation-for-Sonelokimab-Palmoplantar-Pustulosis-PPP-and-Provides-Details-on-Upcoming-Investor-Day.html"
X Link 2026-02-02T13:02Z [----] followers, [----] engagements
"$EXEL Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer. PDUFA December [--] [----]. https://www.businesswire.com/news/home/20260130221586/en/Exelixis-Announces-U.S.-FDA-Accepted-the-New-Drug-Application-for-Zanzalintinib-in-Combination-with-an-Immune-Checkpoint-Inhibitor-for-Patients-with-Metastatic-Colorectal-Cancer"
X Link 2026-02-02T13:03Z [----] followers, [----] engagements
"$AMGN ends Autoimmune alliance With Kyowa Kirin Amid Safety Efficacy Questions. OX40 continues to lose its shine (cc: $SNY) - should be value-adding for $CRVS and $NKTR (new moa). https://www.biospace.com/business/amgen-ends-autoimmune-alliance-with-kyowa-kirin-amid-safety-efficacy-questions https://www.biospace.com/business/amgen-ends-autoimmune-alliance-with-kyowa-kirin-amid-safety-efficacy-questions"
X Link 2026-02-02T13:33Z [----] followers, [----] engagements
"$TERN $37 @zohmbastic $TERN @zohmbastic https://t.co/1DhJeajJcl $TERN @zohmbastic https://t.co/1DhJeajJcl"
X Link 2026-02-02T20:01Z [----] followers, [----] engagements
"$ABVX #Abivax: the success story of a French biotech company courted by major pharmaceutical companies. via @libe https://www.liberation.fr/economie/abivax-ou-la-reussite-dune-biotech-francaise-courtisee-par-les-grands-labos-20260202_HU5WGEM73BDRHNAXPW6U5LUFUA/ https://www.liberation.fr/economie/abivax-ou-la-reussite-dune-biotech-francaise-courtisee-par-les-grands-labos-20260202_HU5WGEM73BDRHNAXPW6U5LUFUA/"
X Link 2026-02-03T06:05Z [----] followers, [----] engagements
"$NVO $NOVOB Novo Nordisk submits Wegovy tablets (oral semaglutide [--] mg) for the treatment of obesity for regulatory approval by ANVISA https://www.novonordisk.com.br/content/nncorp/br/pt/noticias-e-imprensa/busca-noticias/novo-nordisk-submete-wegovy-comprimidos-semaglutida-oral-25-mg-para-tratamento-da-obesidade-a-aprovacao-regulatoria-da-anvisa.html https://www.novonordisk.com.br/content/nncorp/br/pt/noticias-e-imprensa/busca-noticias/novo-nordisk-submete-wegovy-comprimidos-semaglutida-oral-25-mg-para-tratamento-da-obesidade-a-aprovacao-regulatoria-da-anvisa.html"
X Link 2026-02-03T09:04Z [----] followers, [----] engagements
"$MRK Announces Fourth-Quarter and Full-Year [----] Financial Results; Highlights Progress Advancing Broad Diverse Pipeline https://www.businesswire.com/news/home/20260203933145/en/Merck-Co.-Inc.-Rahway-N.J.-USA-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-Highlights-Progress-Advancing-Broad-Diverse-Pipeline https://www.businesswire.com/news/home/20260203933145/en/Merck-Co.-Inc.-Rahway-N.J.-USA-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-Highlights-Progress-Advancing-Broad-Diverse-Pipeline"
X Link 2026-02-03T11:30Z [----] followers, [----] engagements
"@a_a_free Winrevair achieved this status in [----] $1.4B in sales acquired through $XLRN takeover. Ohtuvayre next.👍 $VRNA"
X Link 2026-02-03T11:41Z [----] followers, [---] engagements
"$PFE Reports Solid Full-Year [----] Results And Reaffirms [----] Guidance https://www.businesswire.com/news/home/20260203145333/en/Pfizer-Reports-Solid-Full-Year-2025-Results-And-Reaffirms-2026-Guidance https://www.businesswire.com/news/home/20260203145333/en/Pfizer-Reports-Solid-Full-Year-2025-Results-And-Reaffirms-2026-Guidance"
X Link 2026-02-03T11:46Z [----] followers, [----] engagements
"$PFE $MTSR Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial https://www.businesswire.com/news/home/20260202566685/en/Pfizers-Ultra-Long-Acting-Injectable-GLP-1-RA-Shows-Robust-and-Continued-Weight-Loss-with-Monthly-Dosing-in-Phase-2b-Trial https://www.businesswire.com/news/home/20260202566685/en/Pfizers-Ultra-Long-Acting-Injectable-GLP-1-RA-Shows-Robust-and-Continued-Weight-Loss-with-Monthly-Dosing-in-Phase-2b-Trial"
X Link 2026-02-03T11:46Z [----] followers, [----] engagements
"$XLRN acquisition is paying off more and more. #Winrevair $VRNA Ohtuvayre should also achieve blockbuster status next year. $MRK Ohtuvayre achieved 178M in Q4 [----]. Will be blockbuster in [----]. $MRK always amazing in their M&A. Hope they will be back to $RVMD soon. Ohtuvayre achieved 178M in Q4 [----]. Will be blockbuster in [----]. $MRK always amazing in their M&A. Hope they will be back to $RVMD soon"
X Link 2026-02-03T11:54Z [----] followers, [----] engagements
"$RLAY Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant HR+/HER2- Advanced Breast Cancer https://www.globenewswire.com/news-release/2026/02/03/3230914/0/en/Relay-Therapeutics-Announces-Zovegalisib-Granted-Breakthrough-Therapy-Designation-by-U-S-FDA-for-PIK3CA-mutant-HR-HER2-Advanced-Breast-Cancer.html https://www.globenewswire.com/news-release/2026/02/03/3230914/0/en/Relay-Therapeutics-Announces-Zovegalisib-Granted-Breakthrough-Therapy-Designation-by-U-S-FDA-for-PIK3CA-mutant-HR-HER2-Advanced-Breast-Cancer.html"
X Link 2026-02-03T12:03Z [----] followers, [----] engagements
"$PFE pushing #obesity pipeline forward. $MTSR cc: $LLY $NVO $VKTX"
X Link 2026-02-03T12:06Z [----] followers, [----] engagements
"$MRK $PFE interesting price action. I prefer $MRK. $XLRN acquisition is paying off more and more. #Winrevair $VRNA Ohtuvayre should also achieve blockbuster status next year. $MRK https://t.co/sCtE1TzOed $XLRN acquisition is paying off more and more. #Winrevair $VRNA Ohtuvayre should also achieve blockbuster status next year. $MRK https://t.co/sCtE1TzOed"
X Link 2026-02-03T15:12Z [----] followers, [----] engagements
"$QURE up 8%. Results of the FDA meeting soon New hope for $QURE investors and people suffering from Huntington's disease. No timing provided shares up 15%. https://t.co/EWdN6apeRw https://t.co/kiliFS07By New hope for $QURE investors and people suffering from Huntington's disease. No timing provided shares up 15%. https://t.co/EWdN6apeRw https://t.co/kiliFS07By"
X Link 2026-02-03T15:15Z [----] followers, 12.5K engagements
"$SRRK at 52-week high surprising strength recently. $NVO will report earnings tomorrow news about $CTLT Or even a buyout Pure speculation but $SRRK would fit into the #NovoNordisk portfolio. $SRRK More clarity. Shares up 13%. $REGN $NVO https://t.co/CBo8VyKGvm https://t.co/gLG5EQ4jH6 $SRRK More clarity. Shares up 13%. $REGN $NVO https://t.co/CBo8VyKGvm https://t.co/gLG5EQ4jH6"
X Link 2026-02-03T15:34Z [----] followers, [----] engagements
"$TERN chart update. Beautiful breakout. Next target $40 (offering price from December). $TERN @zohmbastic https://t.co/1DhJeajJcl $TERN @zohmbastic https://t.co/1DhJeajJcl"
X Link 2026-02-03T15:52Z [----] followers, [----] engagements
"$NVO $NOVOB disappointing guidance. $LLY https://www.globenewswire.com/news-release/2026/02/03/3231380/0/en/Novo-Nordisk-releases-2026-sales-and-operating-profit-outlook.html https://www.globenewswire.com/news-release/2026/02/03/3231380/0/en/Novo-Nordisk-releases-2026-sales-and-operating-profit-outlook.html"
X Link 2026-02-03T17:05Z [----] followers, [----] engagements
"$NVS delivered high single-digit sales growth achieved 40% core margin and further advanced the pipeline in [----] https://www.globenewswire.com/news-release/2026/02/04/3231748/0/en/Novartis-delivered-high-single-digit-sales-growth-achieved-40-core-margin-and-further-advanced-the-pipeline-in-2025.html https://www.globenewswire.com/news-release/2026/02/04/3231748/0/en/Novartis-delivered-high-single-digit-sales-growth-achieved-40-core-margin-and-further-advanced-the-pipeline-in-2025.html"
X Link 2026-02-04T06:14Z [----] followers, [----] engagements
"$NVS #Scemblix sales up 85% to $596M last year. $TERN"
X Link 2026-02-04T06:20Z [----] followers, [----] engagements
"$NVO $NOVOB #NovoNordisk patent landscape. $LLY"
X Link 2026-02-04T06:35Z [----] followers, 19.4K engagements
"$NVO $NOVOB #NovoNordisk Pipeline overview. $AKRO $LLY"
X Link 2026-02-04T06:36Z [----] followers, [----] engagements
"WuXi Biologics and $VRTX Sign License and Research Service Agreement for T-cell Engager https://www.prnewswire.com/news-releases/wuxi-biologics-and-vertex-sign-license-and-research-service-agreement-for-t-cell-engager-302677027.html https://www.prnewswire.com/news-releases/wuxi-biologics-and-vertex-sign-license-and-research-service-agreement-for-t-cell-engager-302677027.html"
X Link 2026-02-04T09:02Z [----] followers, [----] engagements
"$LLY reports fourth-quarter [----] financial results and provides [----] guidance https://www.prnewswire.com/news-releases/lilly-reports-fourth-quarter-2025-financial-results-and-provides-2026-guidance-302678376.html https://www.prnewswire.com/news-releases/lilly-reports-fourth-quarter-2025-financial-results-and-provides-2026-guidance-302678376.html"
X Link 2026-02-04T11:48Z [----] followers, [----] engagements
"$AMGN $ARWR #Olpasiran"
X Link 2026-02-04T12:39Z [----] followers, [----] engagements
"$ABBV Reports Full-Year and Fourth-Quarter [----] Financial Results https://news.abbvie.com/2026-02-04-AbbVie-Reports-Full-Year-and-Fourth-Quarter-2025-Financial-Results https://news.abbvie.com/2026-02-04-AbbVie-Reports-Full-Year-and-Fourth-Quarter-2025-Financial-Results"
X Link 2026-02-04T12:49Z [----] followers, [----] engagements
"$SRPT Announces Approval of Clinical Trial Application for SRP-1005 Its Investigational Treatment for Huntingtons Disease. $QURE https://www.businesswire.com/news/home/20260204133666/en/Sarepta-Therapeutics-Announces-Approval-of-Clinical-Trial-Application-for-SRP-1005-Its-Investigational-Treatment-for-Huntingtons-Disease https://www.businesswire.com/news/home/20260204133666/en/Sarepta-Therapeutics-Announces-Approval-of-Clinical-Trial-Application-for-SRP-1005-Its-Investigational-Treatment-for-Huntingtons-Disease"
X Link 2026-02-04T13:56Z [----] followers, [----] engagements
"$HIMS $GRAL Do More by Knowing More: the Hims & Hers Multi-Cancer Test by Galleri https://news.hims.com/newsroom/do-more-by-knowing-more-the-hims-hers-multi-cancer-test-by-galleri-r https://news.hims.com/newsroom/do-more-by-knowing-more-the-hims-hers-multi-cancer-test-by-galleri-r"
X Link 2026-02-04T14:28Z [----] followers, [----] engagements
"$MRK 🙃🙃🙃 $MRK 🙃 https://t.co/I08i82X0En $MRK 🙃 https://t.co/I08i82X0En"
X Link 2026-02-04T14:47Z [----] followers, [----] engagements
"$MRK Enlicitide will be a blockbuster. In the phase [--] CORALreef Lipids trial the oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by 57% at [--] weeks and also lowered non-HDL cholesterol apolipoprotein B and lipoprotein(a). Adverse events were similar in the two groups. Full trial results: https://t.co/00HU7ZH7JY In the phase [--] CORALreef Lipids trial the oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by 57% at [--] weeks and also lowered non-HDL cholesterol apolipoprotein B and lipoprotein(a). Adverse events were similar in the two groups. Full trial results:"
X Link 2026-02-05T08:41Z [----] followers, [----] engagements
"$MRK PT raised from $105 to $131 at DZ Bank "BUY". I think that $MRK will soon make additional acquisitions in the oncology sector. Some potential targets: $TERN $VSTM $DAWN $IMCR $CELC $MRK 🙃🙃🙃 https://t.co/2IZD9vcjnn $MRK 🙃🙃🙃 https://t.co/2IZD9vcjnn"
X Link 2026-02-05T09:30Z [----] followers, [----] engagements
"$BMY Reports Fourth Quarter and Full-Year Financial Results for [----] https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_financials/quarterly_reports/2025/BMY-Q4-2025-Earnings-Press-Release.pdf https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_financials/quarterly_reports/2025/BMY-Q4-2025-Earnings-Press-Release.pdf"
X Link 2026-02-05T12:00Z [----] followers, [----] engagements
"$BMY #Camzyos growth impressive. I am curious to see how the launch of $CYTK will affect market share. Cobenfy disappointing. $KRTX"
X Link 2026-02-05T12:02Z [----] followers, [----] engagements
"$OCUL Reports Fourth Quarter and Full Year [----] Financial Results and Business Highlights - SOL-1 Phase [--] superiority trial results remain masked to date. SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting. https://www.globenewswire.com/news-release/2026/02/05/3232830/0/en/Ocular-Therapeutix-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Highlights.html https://www.globenewswire.com/news-release/2026/02/05/3232830/0/en/Ocular-Therapeutix-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Highlights.html"
X Link 2026-02-05T12:05Z [----] followers, [----] engagements
"$BMY comparison to Q3 [----]. Krazati sales actually declined from Q4 to Q3 Cobenfy sluggish Camzyos performing well. But $CYTK is in the starting blocks and I am excited to see what the next few quarters bring. $MRTX $KRTX $MYOK $BMY #Camzyos growth impressive. I am curious to see how the launch of $CYTK will affect market share. Cobenfy disappointing. $KRTX https://t.co/Av4uWrWi2v $BMY #Camzyos growth impressive. I am curious to see how the launch of $CYTK will affect market share. Cobenfy disappointing. $KRTX https://t.co/Av4uWrWi2v"
X Link 2026-02-05T12:11Z [----] followers, [----] engagements
"What are patents for Just asking for a friend. $HIMS $NVO $NVO $NOVOB #NovoNordisk patent landscape. $LLY https://t.co/23JBfcj7xb $NVO $NOVOB #NovoNordisk patent landscape. $LLY https://t.co/23JBfcj7xb"
X Link 2026-02-05T14:14Z [----] followers, 12.5K engagements
"$HIMS $NVO statement "on illegal mass compounding and deceptive advertising by Hims & Hers" @trader_53 https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.htmlid=916489 @trader_53 Pressure from all sides. It is also doubtful whether $HIMS is acting legally. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.htmlid=916489 @trader_53 Pressure from all sides. It is also doubtful whether $HIMS is acting legally"
X Link 2026-02-05T15:53Z [----] followers, [----] engagements
"$IDIA #Idorsia Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease. $SGMO $QURE https://www.globenewswire.com/news-release/2026/02/06/3233573/0/en/Clear-route-to-registration-positions-lucerastat-as-the-potential-first-oral-therapy-for-all-patients-with-Fabry-disease.html https://www.globenewswire.com/news-release/2026/02/06/3233573/0/en/Clear-route-to-registration-positions-lucerastat-as-the-potential-first-oral-therapy-for-all-patients-with-Fabry-disease.html"
X Link 2026-02-06T06:04Z [----] followers, [----] engagements
"$BAYN #Bayer's asundexian demonstrated a substantial [--] percent reduction in stroke after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack with no increase in ISTH major bleeding versus placebo. $BMY https://www.bayer.com/media/en-us/bayers-asundexian-demonstrated-a-substantial-26-percent-reduction-in-stroke-after-a-non-cardioembolic-ischemic-stroke-or-high-risk-transient-ischemic-attack-with-no-increase-in-isth-major-bleeding-versus-placebo/"
X Link 2026-02-06T06:35Z [----] followers, [----] engagements
"$ABBV CSO about ABBV-295 (formerly GUBamy). Additional data this year + moving into phase II near the end of the year (expected). Could trigger a milestone payment to $GUBRA. (Source: Q4 [----] Earnings call transcript of AbbVie). $LLY $NVO $VKTX"
X Link 2026-02-06T09:16Z [----] followers, [----] engagements
"$BIIB Reports Fourth Quarter and Full Year [----] Results. #Eisai #BioArctic https://investors.biogen.com/news-releases/news-release-details/biogen-reports-fourth-quarter-and-full-year-2025-results https://investors.biogen.com/news-releases/news-release-details/biogen-reports-fourth-quarter-and-full-year-2025-results"
X Link 2026-02-06T11:15Z [----] followers, [----] engagements
"$PFE FDA Grants Priority Review for HYMPAVZI (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need https://www.businesswire.com/news/home/20260205107500/en/FDA-Grants-Priority-Review-for-HYMPAVZI-marstacimab-sBLA-for-the-Treatment-of-Two-Hemophilia-A-or-B-Patient-Populations-with-Significant-Medical-Need https://www.businesswire.com/news/home/20260205107500/en/FDA-Grants-Priority-Review-for-HYMPAVZI-marstacimab-sBLA-for-the-Treatment-of-Two-Hemophilia-A-or-B-Patient-Populations-with-Significant-Medical-Need"
X Link 2026-02-06T12:19Z [----] followers, [---] engagements
"$QURE Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in -Gal A Enzyme Activity in Patients with Fabry Disease. $SGMO https://www.globenewswire.com/news-release/2026/02/06/3233740/0/en/uniQure-Announces-Updated-Preliminary-AMT-191-Phase-I-IIa-Data-Showing-Sustained-Increases-in-%CE%B1-Gal-A-Enzyme-Activity-in-Patients-with-Fabry-Disease.html"
X Link 2026-02-06T12:20Z [----] followers, [----] engagements
"$ROIV Positive Phase [--] Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December [--] [----] https://www.globenewswire.com/news-release/2026/02/06/3233728/34323/en/Roivant-Announces-Positive-Phase-2-Results-for-Brepocitinib-in-Cutaneous-Sarcoidosis-CS-and-Reports-Financial-Results-for-the-Third-Quarter-Ended-December-31-2025.html"
X Link 2026-02-06T12:21Z [----] followers, [----] engagements
"AMT-191 active drug dose-limiting toxicity (liver enzymes) but seems manageable. $QURE have to collect more data to substantiate the long-term medical benefits with an acceptable safety profile. Early solid data but no home run. Short term the FDA feedback on HD will be key. $QURE Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in -Gal A Enzyme Activity in Patients with Fabry Disease. $SGMO https://t.co/drF42zzAKj $QURE Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in -Gal A Enzyme Activity in Patients with Fabry Disease."
X Link 2026-02-06T13:07Z [----] followers, [----] engagements
"Belgian fibrotic disease biotech $AGMB prices IPO at $16 midpoint raising $200M. At pricing AgomAb commands a fully diluted market value of $875M. High valuation imo. $UTHR https://www.renaissancecapital.com/IPO-Center/News/116801/Belgian-fibrotic-disease-biotech-AgomAb-Therapeutics-prices-IPO-at-$16-midp https://www.renaissancecapital.com/IPO-Center/News/116801/Belgian-fibrotic-disease-biotech-AgomAb-Therapeutics-prices-IPO-at-$16-midp"
X Link 2026-02-06T13:29Z [----] followers, [----] engagements
"$GILD $KITE FDA Approves Label Update for Kites Yescarta for Relapsed/Refractory Primary Central Nervous System Lymphoma https://www.businesswire.com/news/home/20260205203420/en/FDA-Approves-Label-Update-for-Kites-Yescarta-for-RelapsedRefractory-Primary-Central-Nervous-System-Lymphoma https://www.businesswire.com/news/home/20260205203420/en/FDA-Approves-Label-Update-for-Kites-Yescarta-for-RelapsedRefractory-Primary-Central-Nervous-System-Lymphoma"
X Link 2026-02-06T13:31Z [----] followers, [----] engagements
"I own shares of $ABVX $NKTR and $PTGX. Looking for dips at $CRVS. $CRVS $NKTR $ABVX $PTGX - cantor nice pic on Immunology Product Performance Across 4Q25. Which begs the questions what the valuations of NEW MOAs hopefully coming to market Yes competition but LARGE markets https://t.co/PqC177ME9c $CRVS $NKTR $ABVX $PTGX - cantor nice pic on Immunology Product Performance Across 4Q25. Which begs the questions what the valuations of NEW MOAs hopefully coming to market Yes competition but LARGE markets https://t.co/PqC177ME9c"
X Link 2026-02-08T08:35Z [----] followers, [----] engagements
"#Innovent Announces Strategic Collaboration with $LLY to Develop New Medicines Globally in Oncology and Immunology https://www.prnewswire.com/news-releases/innovent-announces-strategic-collaboration-with-lilly-to-develop-new-medicines-globally-in-oncology-and-immunology-302682009.html https://www.prnewswire.com/news-releases/innovent-announces-strategic-collaboration-with-lilly-to-develop-new-medicines-globally-in-oncology-and-immunology-302682009.html"
X Link 2026-02-08T13:56Z [----] followers, [----] engagements
"$SNY rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia https://www.globenewswire.com/news-release/2026/02/09/3234232/0/en/Press-Release-Sanofi-s-rilzabrutinib-designated-breakthrough-therapy-in-the-US-and-orphan-drug-in-Japan-for-the-treatment-of-warm-autoimmune-hemolytic-anemia.html https://www.globenewswire.com/news-release/2026/02/09/3234232/0/en/Press-Release-Sanofi-s-rilzabrutinib-designated-breakthrough-therapy-in-the-US-and-orphan-drug-in-Japan-for-the-treatment-of-warm-autoimmune-hemolytic-anemia.html"
X Link 2026-02-09T06:03Z [----] followers, [----] engagements
"$BONEX #Bonesupport PT from SEK [---] to SEK [---] at ABGSC "BUY". "Attractive entry point into growth case". Sales and outlook already pre-announced ahead of Q4"
X Link 2026-02-09T07:18Z [----] followers, [----] engagements
"$LLY to acquire Orna Therapeutics to advance cell therapies https://www.prnewswire.com/news-releases/lilly-to-acquire-orna-therapeutics-to-advance-cell-therapies-302682157.html https://www.prnewswire.com/news-releases/lilly-to-acquire-orna-therapeutics-to-advance-cell-therapies-302682157.html"
X Link 2026-02-09T12:01Z [----] followers, [----] engagements
"$NVO $NOVOB takes legal action against Hims & Hers to protect patients from unsafe knock-off Wegovy and Ozempic. $HIMS https://www.globenewswire.com/news-release/2026/02/09/3234381/0/en/Novo-Nordisk-takes-legal-action-against-Hims-Hers-to-protect-patients-from-unsafe-knock-off-Wegovy-and-Ozempic.html https://www.globenewswire.com/news-release/2026/02/09/3234381/0/en/Novo-Nordisk-takes-legal-action-against-Hims-Hers-to-protect-patients-from-unsafe-knock-off-Wegovy-and-Ozempic.html"
X Link 2026-02-09T12:14Z [----] followers, [----] engagements
"$TERN Interesting situation both from a chart and fundamental perspective. Clear takeover candidate imo. Huge CML opportunity. $NVS #Scemblix $TERN initiated with an Outperform at Leerink. PT $58 $TERN initiated with an Outperform at Leerink. PT $58"
X Link 2026-02-09T13:02Z [----] followers, [----] engagements
"Aerska Raises $39M Series A Financing led by EQT Dementia Fund and age1 to Systemically Deliver RNA Medicines to the Brain. $EQT https://www.globenewswire.com/news-release/2026/02/09/3234456/0/en/Aerska-Raises-39M-Series-A-Financing-led-by-EQT-Dementia-Fund-and-age1-to-Systemically-Deliver-RNA-Medicines-to-the-Brain.html https://www.globenewswire.com/news-release/2026/02/09/3234456/0/en/Aerska-Raises-39M-Series-A-Financing-led-by-EQT-Dementia-Fund-and-age1-to-Systemically-Deliver-RNA-Medicines-to-the-Brain.html"
X Link 2026-02-09T14:30Z [----] followers, [----] engagements
"#BioArctic BLA for subcutaneous formulation of Leqembi designated for Priority Review in China. $BIIB #Eisai https://www.bioarctic.com/en/bla-for-subcutaneous-formulation-of-leqembi-designated-for-priority-review-in-china/ https://www.bioarctic.com/en/bla-for-subcutaneous-formulation-of-leqembi-designated-for-priority-review-in-china/"
X Link 2026-02-10T06:19Z [----] followers, [---] engagements
"$RGNX FDA issues Complete Response Letter for RGX-121 (clemidsogene lanparvovec) for treatment of Mucopolysaccharidosis II (MPS II) https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-announces-regulatory-update-rgx-121-bla-mps-ii https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-announces-regulatory-update-rgx-121-bla-mps-ii"
X Link 2026-02-10T07:00Z [----] followers, [---] engagements
"$INCY Reports Fourth Quarter and Full Year [----] Financial Results https://www.businesswire.com/news/home/20260210471010/en/Incyte-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results https://www.businesswire.com/news/home/20260210471010/en/Incyte-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results"
X Link 2026-02-10T12:01Z [----] followers, [---] engagements
"$NKTR rollercoaster pre-market. All in all good results imo. $NKTR maintenance. https://t.co/eSC08JGFAN $NKTR maintenance. https://t.co/eSC08JGFAN"
X Link 2026-02-10T12:12Z [----] followers, [----] engagements
"$INCY betaville rumor one year ago has turned out to be nothing The Jakafi patent cliff is drawing ever closer - and #Incyte is likely to engage in M&A itself. $SNDX could be a potential target; $INCY has the cash to buy them. https://investor.incyte.com/news-releases/news-release-details/incyte-reports-fourth-quarter-and-full-year-2025-financial $INCY again #betaville rumor. I can't imagine a takeover. https://t.co/CMobzw0l34 https://investor.incyte.com/news-releases/news-release-details/incyte-reports-fourth-quarter-and-full-year-2025-financial $INCY again #betaville rumor. I can't imagine"
X Link 2026-02-10T12:20Z [----] followers, [----] engagements
"$EVMN Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis. $NKTR $KYMR $CRVS https://www.businesswire.com/news/home/20260210709064/en/Evommune-Announces-Positive-Top-line-Data-from-Phase-2a-Proof-of-Concept-Trial-of-EVO301-in-Moderate-to-Severe-Atopic-Dermatitis https://www.businesswire.com/news/home/20260210709064/en/Evommune-Announces-Positive-Top-line-Data-from-Phase-2a-Proof-of-Concept-Trial-of-EVO301-in-Moderate-to-Severe-Atopic-Dermatitis"
X Link 2026-02-10T12:33Z [----] followers, [----] engagements
"$NKTR slides out. https://ir.nektar.com/static-files/1432c99b-ce12-46c5-9aef-ba5487f06a88 https://ir.nektar.com/static-files/1432c99b-ce12-46c5-9aef-ba5487f06a88"
X Link 2026-02-10T13:02Z [----] followers, [----] engagements
"$NKTR upcoming milestones. https://ir.nektar.com/static-files/1432c99b-ce12-46c5-9aef-ba5487f06a88 https://ir.nektar.com/static-files/1432c99b-ce12-46c5-9aef-ba5487f06a88"
X Link 2026-02-10T13:03Z [----] followers, [----] engagements
"$NKTR nearing +30-50%. $NKTR seems BULL case met per Jefferies estimates 30-50%upside 🤷♂ https://t.co/B55R5VBwAP $NKTR seems BULL case met per Jefferies estimates 30-50%upside 🤷♂ https://t.co/B55R5VBwAP"
X Link 2026-02-10T13:43Z [----] followers, [----] engagements
"AD companies: $NKTR $0.94B market cap $KYMR $6.32B market cap $APGE $4.24B market cap $CRVS $1.68B market cap"
X Link 2026-02-10T13:56Z [----] followers, 14.5K engagements
"$GILD Announces Fourth Quarter and Full Year [----] Financial Results https://www.businesswire.com/news/home/20260210935221/en/Gilead-Sciences-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results https://www.businesswire.com/news/home/20260210935221/en/Gilead-Sciences-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results"
X Link 2026-02-10T21:02Z [----] followers, [---] engagements
"$MDGL Expands its #MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical #siRNA Programs https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-expands-its-mash-pipeline-exclusive-global-licensing https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-expands-its-mash-pipeline-exclusive-global-licensing"
X Link 2026-02-11T10:33Z [----] followers, [----] engagements
"$NBIX Reports Fourth-Quarter and Full-Year [----] Financial Results and Provides Financial Expectations for [----] https://www.prnewswire.com/news-releases/neurocrine-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-financial-expectations-for-2026-302685532.html https://www.prnewswire.com/news-releases/neurocrine-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-financial-expectations-for-2026-302685532.html"
X Link 2026-02-11T21:05Z [----] followers, [----] engagements
"$NBIX #Crenessity growth is impressive. Bodes well for a potential launch of Atumelnant from $CRNX for the treatment of CAH in the long-term. $NBIX Reports Fourth-Quarter and Full-Year [----] Financial Results and Provides Financial Expectations for [----] https://t.co/wg8tgQQ7WW $NBIX Reports Fourth-Quarter and Full-Year [----] Financial Results and Provides Financial Expectations for [----] https://t.co/wg8tgQQ7WW"
X Link 2026-02-11T21:40Z [----] followers, [----] engagements
"$VKTX shares up 10% AH. Good progress Oral VK2735 advancing into phase [--] low cash burn in Q4 and strong cash position. Some M&A speculations heating up again soon Long $VKTX. $NVO $LLY #Obesity $VKTX Reports Fourth Quarter and Year-End [----] Financial Results and Provides Corporate Update https://t.co/nfqmCkqmE6 $VKTX Reports Fourth Quarter and Year-End [----] Financial Results and Provides Corporate Update https://t.co/nfqmCkqmE6"
X Link 2026-02-11T21:50Z [----] followers, [----] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing